According to a study by Gao et al., after administering ipilimumab (anti-CTLA-4) therapy to patients with prostate cancer, the presence of VISTA and PD-L1 inhibitory molecules was observed to increase within the macrophages in the treated tumors (49). Here, CD274 is linked to prostate carcinoma.